Login
Companies $VOR
$18.83 -$0.14 (0.74%) After hours
Vor Biopharma Inc. logo

Vor Biopharma Inc.

vorbio.com

What Do They Do?

Develops telitacicept, a drug candidate for people with autoimmune diseases such as generalized myasthenia gravis and Sjögren’s disease.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +89% (Loss)
vs −$812.7M in Q3 FY2025
  • Nov 11, 2026 Vor Bio expands its RemeGen license to include RC298 The amended agreement gives Vor exclusive development and commercialization rights outside Greater China; RemeGen leads RC298’s preclinical and Phase 1 development in China.

From blood cancer to autoimmunity The earlier report centers on engineered stem-cell treatments for blood cancers; the latest centers on telitacicept for autoimmune diseases and says the prior clinical and manufacturing operations were wound down.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support